Erlotinib for the Treatment of Non-Small Cell Lung Cancer Technology Appraisal
Country of origin: UK
If the overall treatment cost is equal, specialists should discuss with patients the potential benefits and risks of erlotinib and docetaxel before deciding which treatment to use.
Erlotinib is not recommended for people with locally advanced or metastatic NSCLC who cannot take docetaxel and have already tried one chemotherapy regimen but it has not worked.
Erlotinib is not recommended for people who have already tried two chemotherapy regimens, including docetaxel, but they haven't worked.
Healthcare professionals should not stop prescribing erlotinib for people who were already taking it when the guidance was issued. These patients should be able to carry on taking erlotinib until they and their specialist decide that it is the right time to stop treatment.
'Lung cancer (non-small-cell) - erlotinib: guidance ' is available online.
Manual for Cancer Services: Chemotherapy Measures October 2018
Sublux radiology app for all medical providers October 2018
Study finds HPV from Oral Sex is linked to Throat Cancer September 2018
Asian-language cancer information resource September 2018
inPractice® Oncology September 2018
Cancer System Performance August 2018